Transcode Therapeutics, Inc. acquired 100% of ABCJ, LLC on October 8, 2025, which includes Polynoma LLC, an immuno-oncology company. The acquisition aims to expand Transcode's biopharmaceutical capabilities, but poses risks that may affect shareholder value.